with previous studies, 10, 11 the Transthyretin Amyloidosis Cardiac Study (TRACS), a prospective cohort study of 29 patients with TTR-CM, demonstrated rapid disease progression, with a median survival from diagnosis of 25.6 months for TRACS patients carrying the V122I TTR mutation and 43.0 months for patients with wild-type disease. 12 Similarly, a recent study in 99 British wild-type TTR-CM patients reported a median survival from diagnosis of 2.71 years (≈35.2 months). 13 Current treatment for TTR-CM focuses on supportive care, with a minor subset receiving heart transplants. 14, 15 Tafamidis meglumine (tafamidis; Pfizer Inc, New York, NY) is a novel compound that binds to the thyroxine-binding sites of the TTR tetramer, inhibiting its dissociation into monomers. 16 By inhibiting tetramer dissociation, tafamidis blocks the rate-limiting step in the TTR amyloid cascade. 4, 17 An 18-month, double-blind, placebo-controlled trial in patients with early stage TTR familial amyloid polyneuropathy (TTR-FAP) because of a TTR V30M mutation demonstrated that tafamidis treatment stabilizes V30M TTR tetramers and slows progression of neurological symptoms that dominate the clinical picture of TTR amyloidosis patients with a V30M mutation. 18 The present phase 2, multicenter, 12-month trial evaluated the safety of oral tafamidis treatment and effects on TTR stability in patients with wild-type or V122I TTR-CM. Many exploratory efficacy variables were also assessed.
Methods

Study Design
This open-label, single-treatment arm study was conducted at 6 clinical sites in the United States. After a screening period of ≤4 weeks, eligible patients with V122I or wild-type TTR-CM were enrolled and assigned to receive 20 mg of tafamidis once daily (QD). Patients achieving the primary end point of TTR stabilization at week 6 continued tafamidis treatment for 12 months. The study was conducted on an outpatient basis with clinical visits at baseline, weeks 2 and 6, and months 3, 6, and 12. Each patient provided informed consent before engaging in any study procedure.
The study was registered at clinicaltrials.gov (identifier NCT00694161) and conducted in compliance with the International Conference on Harmonization Guidance for Industry on Good Clinical Practice, local country regulations, and ethical principles described in the Declaration of Helsinki (Washington 2002). The complete study protocol was approved by institutional review boards at all study sites. Subsequently, approved amendments to the study protocol clarified monitoring of safety data, increased sample size, allowed identification of amyloid in biopsy specimens by mass spectrometry, and required TTR genotyping during screening for patients without documented diagnosis of TTR-CM. All authors had access to all the data in the study.
Study Population
To be eligible, men and postmenopausal women aged ≥40 years were required to have V122I or wild-type TTR-CM verified by the presence of amyloid in cardiac biopsy tissue, or left ventricular wall thickness of >12 mm (assessed by echocardiography) and presence of amyloid in noncardiac biopsy tissue. The presence of TTR amyloid was determined by Congo red stain, Alcian blue stain plus immunohistochemical TTR analysis, or mass spectrometry. A subset of enrolled patients (V122I: n=1; wild-type: n=6) had participated in the observational TRACS study. 12 Optimal management of heart failure symptoms with a stable drug regimen for ≥4 weeks and, if using a β-blocker, a stable dose for ≥3 months before enrollment were required. Exclusion criteria included primary or secondary amyloidosis, previous liver or heart transplant, positive results for hepatitis B surface antigen, hepatitis C virus, or HIV, moderate or severe hepatic impairment, abnormal liver function (alanine transaminase and aspartate transaminase >2× the upper limit of normal), previous nonamyloid cardiac disease (eg, obstructive coronary artery disease and active nonamyloid cardiomyopathy), or any comorbidity anticipated to limit survival to <12 months. Chronic use of nonsteroidal anti-inflammatory drugs (with the exception of acetylsalicylic acid, etodolac, ibuprofen, indomethacin, ketoprofen, nabumetone, naproxen, nimesulide, piroxicam, and sulindac) was prohibited.
Interventions
In addition to receiving the standard of care, all enrolled patients were assigned to self-administer an oral capsule containing 20 mg of tafamidis meglumine QD for 12 months. Tafamidis was the only active ingredient in the supplied gel capsules containing 20 mg of tafamidis meglumine (d-glucitol, 1-deoxy- 
Outcome Measures
TTR stabilization was determined by a validated immunoturbidimetric assay (performed by Genzyme Analytic Services, Los Angeles, CA). 16 Briefly, plasma samples were collected and steady-state TTR tetramer stability was determined by comparing TTR tetramer concentration before and after urea denaturation. The ratio of tetramer level postdenaturation to tetramer level predenaturation was termed the fraction of initial (FOI). Percent stabilization was determined by comparing the FOI at each on-drug time point to the FOI at baseline using the following formula:
The stabilization cut-off value for this study was derived from a phase 1 study in healthy volunteers (Pfizer Inc, data on file). Percent stabilization values falling above the 95% confidence interval in healthy volunteers were classified as stabilized.
Incidence of mortality and hospitalization was assessed individually and jointly as a composite exploratory end point, where the cause of death or hospitalization was determined by the principal investigator. Analysis of additional exploratory efficacy end points (assessed by echocardiography, chest x-ray, cardiac MRI, and 24-hour Holter monitoring) was conducted at baseline and months 6 and 12. Echocardiography and cardiac MRI were performed using standard techniques, and images were centrally read by blinded core laboratory personnel to ensure consistent interpretation. Functional status of patients with heart failure was assessed using the New York Heart Association classification criteria at baseline, week 6, and months 3, 6, and 12. Cardiac biomarkers (troponin I, troponin T, and N-terminal prohormone brain natriuretic peptide [NT-proBNP]) were monitored at each study visit. Other outcomes included 6-minute walk test (6MWT) and several measures of health-related quality of life: patient global assessment, Kansas City Cardiomyopathy Questionnaire, 19 and Short Form 36 20 ; these were assessed at baseline and months 3, 6, and 12.
Safety and Tolerability
Adverse events (AEs), including serious AEs (SAEs), were collected at study visits or by monthly telephone calls. Additional measures of safety included vital signs, physical examinations, 12-lead ECGs, and laboratory assessment of blood and urine samples performed during each clinic visit.
Deaths and SAEs were reviewed bimonthly by an independent data monitoring committee. The data monitoring committee could recommend study termination at any time if they determined that the drug was causing undue harm to patients.
Statistical Analysis
Analysis of stabilization, safety, and efficacy end points was based on the intent-to-treat population, including all enrolled patients who received ≥1 dose of tafamidis. In light of the small number of subjects with V122I enrolled (n=4), this article focuses on the wild-type subjects with data for subgroups by TTR genotype available in the Data Supplement. The primary objective was to assess TTR stability after 6 weeks of tafamidis treatment compared with baseline, and safety of tafamidis treatment. Secondary objectives included the determination of TTR stabilization after 6 and 12 months of treatment. The proportion of patients who achieved stabilization was determined at each point, and 95% confidence intervals were calculated using the exact binomial method.
The original protocol planned a sample size of 20 which was increased to ≤40 with a protocol amendment to obtain additional safety and pharmacodynamic data and because calculations with theoretical point estimates indicated that such a sample would adequately characterize 95% confidence intervals for the percent of TTR-CM patients reaching the primary end point.
Exploratory efficacy end points assessed by echocardiography, cardiac MRI, 24-hour Holter monitoring, chest x-ray, New York Heart Association classification, 6MWT, biomarker concentrations, and health-related quality of life measurements were descriptively summarized by visit or by patients. Baseline and change from baseline values of variables with log-normal distribution were log-transformed, and least square (LS) means were estimated using a repeated measures analysis of covariance model with change from baseline as the dependent variable. The estimated LS mean and SE were then back transformed and presented.
All-cause hospitalizations and deaths, as well as cardiovascular hospitalizations and deaths, were summarized by the number, rate of occurrence, and time from diagnosis of TTR-CM. Safety summaries included the number and percent of patients reporting AEs (including SAEs).
Results
Patient Demographics and Baseline Characteristics
In total, 35 patients (V122I, n=4; wild-type, n=31) were screened, enrolled, and treated between August 2008 and January 2010, with data on the wild-type subjects being the focus of this article (Table 1 ) and data for subgroups by TTR genotype available in the Data Supplement. Of the 31 wild-type patients, 30 (96.8%) had TTR amyloid proven on a cardiac biopsy and only 1 (3.2%) was included based on the presence of TTR amyloid in a noncardiac biopsy and left ventricular wall thickness of >12 mm. Three patients discontinued the 12-month study: 1 withdrew to undergo treatment for glioblastoma multiforme; the other 2 died (1 immunoglobulin light chain [AL] amyloidosis and 1 hemorrhagic stroke). Most patients reported mild to moderate symptoms of heart failure at baseline; 96.8% were New York Heart Association class I or II (Table 2 ). In addition, patients frequently had a history of atrial fibrillation (20 cases), heart block (11 cases), and carpal tunnel syndrome (11 cases). All patients took ≥1 medication before study entry; the most common drug classes were loop diuretics (90.3%), anticoagulants (71.0%), aspirin (61.3%), statins (51.6%), angiotensin-converting enzyme inhibitors (48.4%), β-blockers (45.2%), and aldosterone antagonists (29.0%). There were no significant changes in the percentage of patients taking these agents and no consistent increase nor decrease in therapy with regard to the dosages of these medications.
During the study, one patient, initially diagnosed with wildtype TTR-CM, discontinued at investigator request after being diagnosed with AL amyloidosis on day 322 (Data Supplement). To accurately reflect the intent-to-treat population, data from this patient are included in this article. However, given that this patient with AL amyloidosis is not expected to respond to tafamidis, efficacy outcomes, excluding data from this patient, are provided in the Data Supplement. NT-proBNP indicates N-terminal prohormone brain natriuretic peptide; NYHA, New York Heart Association; TTR, transthyretin; and TTR-CM, transthyretincardiomyopathy.
*These numbers include patients with a history of atrial fibrillation that had resolved at the time of study entry. †Heart blocks included atrioventricular block of first degree, bifascicular block, left bundle branch block, and right bundle branch block. May 2015
TTR Stabilization (Primary End Point)
Tafamidis effectively stabilized TTR in 30 of 31 patients (96.8%) at week 6 ( Table 3 ). The only patient lacking stabilization did not have any safety concerns and remained in the study after careful review by the principal investigator and notification of the internal review board. TTR stabilization was not achieved for this patient throughout the study, and the clinical course of the patient was similar to that of the overall population. TTR stabilization was observed in 27 of 30 patients (90.0%) at month 6 and in 25 of 28 (89.3%) at month 12.
Safety
Death or Cardiovascular Hospitalization
Two patients died during the study period: 1 patient originally classified as wild-type TTR-CM died from complications resulting from AL amyloidosis, as discussed above. The other died on study day 105 of a hemorrhagic stroke occurring after a fall.
During 12 months of tafamidis treatment, 7 patients (22.6%) were hospitalized because of cardiovascular events. Two of these had 1 cardiovascular hospitalization each, and 5 had 2 cardiovascular hospitalizations each. Six of the 12 cardiovascular hospitalizations were assessed to be related to heart failure.
Serious Adverse Events
SAEs were experienced by 13 of 31 patients (41.9%; Table 4 ). Most were cardiac events, such as worsening heart failure (8 patients, 25.8%) and atrial fibrillation (3 patients, 9.7%). In addition, 2 patients had an SAE categorized as syncope and 1 of these had a pacemaker implanted. One additional patient had an SAE categorized as pacemaker insertion. Four patients experienced SAEs that were assessed as possibly related to tafamidis. These included ataxia, falls, heart failure, a fallinduced hemorrhagic stroke, and syncope. With the exception of the 2 deaths, all patients with an SAE had recovered or were improving by the study end.
Adverse Events
Reflecting the study populations' underlying cardiac disease, elderly status, and comorbid conditions, all 31 patients experienced ≥1 AE during the study (Data Supplement). The most frequent AEs were symptoms or episodes of heart failure, such as dyspnea, worsening heart failure, and edema. Seven of 31 patients (22.6%) had an AE of diarrhea (including 2 enrolled with an ongoing medical history of diarrhea), and 5 (16.1%) had an AE of weight gain which was, however, not corroborated by changes in their body weight from baseline to month 12 (median: -2.1 kg; range: -10 to 2 kg).
Cardiac Assessments
Echocardiogram assessment demonstrated extensive cardiac involvement in all patients with a baseline assessment (n=30; Table 5 ). All patients (100%) demonstrated markedly increased left ventricular wall thickness (interventricular septum and left ventricular posterior wall). Evidence of elevated left ventricular (high E/E′ septal ratio) and right ventricular (absent vena cava respiratory variations) cardiac filling pressures was seen in 73.7% and 64.0% of patients, respectively; 43.3% had an ejection fraction of <50%. There were no consistent clinically relevant changes in these echocardiogram parameters during 12 months of tafamidis treatment. As a result of the high prevalence of patients with pacemakers (n=15; 13 before and 2 during the study), only a limited subset of patients underwent cardiac MRI (Data Supplement).
Nearly all patients had electrocardiographic (100%) and Holter monitoring (80.0%) abnormalities at enrollment. The most common pretreatment ECG abnormalities were abnormal conduction (90.3%), abnormal rhythm (67.7%), pathological Q waves (19.4%), and abnormal T wave (19.4%). The incidence of treatment-emergent ECG abnormalities was low, with no adverse effect of tafamidis on rhythm or conduction. Holter monitoring abnormalities detected at baseline were indicative of intermittent dysrhythmias and included nonsustained ventricular tachycardia (56.7%), atrial tachycardia (36.7%), atrial fibrillation/flutter (20.0%), and sinus pause (6.7%; Table 6 ). Consistent with a study population with advanced cardiac disease, treatment-emergent new onset atrial fibrillation/flutter was reported in 8 of 18, nonsustained ventricular tachycardia in 4 of 11, and sinus pause in 5 of 24 patients at month 12.
At baseline, the median NT-proBNP concentration was elevated (3178 pg/mL; range, 719-18 401 pg/mL; normal upper limit, 300 pg/mL), and all but 1 patient had values indicative of a high probability of heart failure (≥1000 pg/mL). 21 There was large variation in NT-proBNP concentrations and changes therein between patients with a nonsignificant estimated LS mean (±SE) increase from baseline to month 12 of 601 (±926) pg/mL (Figure 1) . The baseline concentration of troponin I was raised in 100% of patients (median, 0.120 ng/mL; range, 0.06-0.41 ng/mL; normal upper limit, 0.04 ng/mL). After an initial decrease from baseline to month 3, there was an increase in troponin I (LS mean [±SE] change from baseline to month 12, 0.037 (±0.020) ng/mL; P<0.05). Troponin T concentrations were raised in 93.5% of patients at baseline (median, 0.030 ng/mL; range, 0.010-0.160 ng/mL; normal upper limit, 0.01 ng/mL), remained stable during the first 3 months of tafamidis treatment, and were higher relative to baseline at month 6 (LS mean [ 
Functional and Quality of Life Assessments
Change in functional walking ability, measured by the 6MWT, was minimal. The mean distance walked decreased by 8.9 meters from baseline to month 12. Categorical analysis confirmed that most patients maintained their walking status ( Figure 2 ). New York Heart Association classification was maintained in 71.4% patients at month 12 and no patient deteriorated by ≥2 classes or dropped to New York Heart Association classification IV. Overall, patients reported preserved E/A indicates ratio of peak mitral early and atrial diastolic contraction velocity; E/E′, ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity; IVC, inferior vena cava; IVRT, isovolumic relaxation time; PASP, pulmonary artery systolic pressure; RA, right atrial; and RAP, right atrial pressure.
*One patient had no echocardiography assessment at baseline. †The number of patients contributing to these outcomes was based on patients having nonmissing baseline and month-12 values. ‡To calculate tricuspid PASP, RAP was estimated based on RA size and IVC size and collapse (normal RA and IVC: RAP estimated as 5 mm Hg; dilated RA and normal IVC: 10 mm Hg; IVC dilated but normal collapse: 15 mm Hg; IVC dilated with reduced or absent collapse: 20 mm Hg). health-related quality of life during the study: the majority of patients (range, 71.4-86.7%) rated their disease status as unchanged or improved (patient global assessment, Figure 3 ) and changes in Kansas City Cardiomyopathy Questionnaire and Short Form 36 scores were minor (Data Supplement).
Clinical Disease Progression
Although clinical indicators of disease progression and treatment response have been delineated in AL amyloidosis, 22 such data are lacking in TTR-CM. In the absence of prospective clearly defined criteria, we operationalized a definition of clinical disease stability in which patients who died, had a hospitalization for a cardiac event, a rise in NT-proBNP of >1000 pg/mL, an increase in serum creatinine of ≥0.5 mg/dL, or a >50-m decline in distance walked in the 6MWT were considered to have progressed during a 12-month period. On the basis of this non-validated definition, 15 of 31 patients progressed while taking 20 mg of tafamidis for 12 months.
Discussion
This phase 2 open-label study demonstrates that tafamidis treatment was effective in achieving and maintaining TTR stabilization in patients with TTR-CM. AEs reported during the study are in line with expectations for an elderly population with significant heart disease and suggest that tafamidis is well tolerated in patients with TTR-CM. Despite small but statistically significant increases in troponin I and T relative to baseline levels, the absence of clinically significant changes in most clinical, biochemical, electrocardiographic, and echocardiographic parameters is consistent with the potential for tafamidis to slow cardiac disease progression.
TTR-stabilizing compounds, such as tafamidis or diflunisal, 23 are expected to limit the progression of TTR amyloidosis by inhibiting tetramer dissociation, the rate-limiting step in TTR amyloid formation. In a randomized, double-blind trial of tafamidis in TTR-FAP patients with a V30M mutation, TTR stabilization was demonstrated in 98% of patients receiving tafamidis and in none of the control subjects (P<0.001) during the 18-month trial. 18 Patients receiving tafamidis experienced significantly less deterioration in neurological and functional status as indexed by Neuropathy Impairment Score for the lower limbs (NIS-LL, P=-0.041) and the Norfolk total quality of life scores (TQoL, P=0.045) in the efficacy evaluable population. Two recent single-arm, open-label studies reported that tafamidis stabilizes tetrameric TTR also in TTR-FAP patients with non-V30M and non-V122I mutations, 24 but that it may be less efficient in preventing disease progression in V30M patients with advanced disease. 25 On the basis of common mechanism of disease, we hypothesized that, like in early stage TTR-FAP, tafamidis might also stabilize TTR tetramers and slow disease progression in patients with TTR-CM.
TTR-stabilizing agents are designed to prevent de novo deposition of TTR amyloid by blocking the rate-limiting step in the TTR amyloid cascade, and because the pathogenesis of all types of TTR amyloidosis is believed to be related to increased tetramer dissociation, TTR tetramer stabilization is a critical first step in demonstrating the potential for tafamidis to slow cardiac disease progression. However, they are not necessarily expected to actively induce the reabsorption of existing amyloid deposits. An alternative approach is TTR gene silencing, which is being evaluated in 2 prospective ongoing clinical trials of antisense oligonucleotides and small interfering RNA in TTR-FAP 26, 27 and a phase 2 study to evaluate RNA interference therapy in patients with TTR cardiac amyloidosis (clinicaltrials.gov identifier: NCT01981837). The safety and efficacy of such an approach are currently unknown. Whether these agents will be comparable, superior, or inferior to TTR stabilization and whether combination therapy will afford clinical benefit are likely to be a focus of ongoing investigation. Results of patient global assessment over the course of tafamidis treatment. Seventy-one percent to 87% of patients assessed their global status as preserved or improved throughout the study when asked, "How do you feel today when compared with when we talked with you at your last clinic visit for this study?" Change is from previous visit and the functional status of 17.2% of patients was excellent, of 44.8% very good; of 34.5% good; of 3.4% fair; and of 0% poor at baseline based on the question, "In general, how do you feel today?" One patient had missing month-3 results.
Although the immunoturbidity assay is well suited to demonstrate TTR stabilization in the vast majority of patients, by definition, a high FOI at baseline necessitates a proportionally larger increase in postdose FOIs to be considered stabilized. Indeed, 4 of the 5 patients who did not achieve consistent TTR stabilization in this study had baseline FOIs of >0.4, range 0.42 to 0.60. In contrast, 29 of 30 patients who were stabilized at every assessment had baseline FOIs of <0.35, range 0.15 to 0.34. It remains to be determined whether a high baseline FOI equates with a higher TTR tetramer stability under physiological conditions that may not be further increased by tafamidis. Another inherent limitation of this assay conducted under nonphysiological conditions is that it was developed as a qualitative assessment of TTR stabilization and not a quantitative measure of the degree of stabilization. Despite these limitations, the assay is an appropriate primary end point for this hypothesis-generating, open-label trial, especially as increases in TTR stability after administration of tafamidis are unlikely to be the result of placebo effects or of natural improvements over time but are highly likely to be treatment-related.
The single-arm design of this study limits the ability to demonstrate efficacy of tafamidis on outcome measures. TTR-CM is a progressive disorder. Published series to date have reported 1-year mortality of 14% to 23% in wild-type TTR-CM subjects. 11, 12, 28 Serial measurements of clinical parameters used in this interventional study were also used in the observational, prospective TRACS study that examined the natural history of 18 untreated wild-type and 11 V122I TTR-CM patients. In the absence of a parallel control cohort, comparison of observed event rates to those observed in TRACS may allow for the safety and exploratory results to be put into context. 12 After 12 months of follow-up, 2 of 18 wild-type TTR-CM patients enrolled in TRACS (11.1%) died and 3 (16.7%) were hospitalized because of cardiovascular events. Looking at median (range) change from baseline to month 12, the NT-proBNP concentration increased by 1487 (-2331 to 4958) pg/mL to 6268 (1206 to 9506) pg/mL; the distance walked in the 6MWT increased by 0.6 (-206 to 39.3) m to 359.5 (166.0 to 665.0) m, and left ventricular ejection fraction monitored by echocardiography decreased by -8.0% (-39.0% to 1.0%) to 50.5% (25.0% to 67.0%). Increases from baseline to month 12 in troponin I (median, 0.02 ng/mL; range, -0.03-0.07 ng/mL; n=8) and troponin T (median, 0.01 ng/mL, range, -0.01-0.09 ng/mL, n=4) observed in TRACS did not markedly exceed those observed in this study. However, in the absence of a parallel control group, it cannot be determined with certainty whether increases in troponin I and T concentrations would have been more pronounced in the absence of tafamidis in the current population. With regard to clinical progression, 15 of 31 (48.4%) of wild-type patients who received 20 mg of tafamidis progressed as defined by either death, cardiovascular hospitalization, a rise in NT-proBNP of >1000 pg/mL, an increase in serum creatinine of ≥0.5 mg/dL, or a decline in the distance walked in the 6MWT of >50 m during the 12-month study period, whereas 21 of 29 (72.4%) of wild-type subjects progressed during the first 12 months of the TRACS study. Whether a higher dose of tafamidis (eg, 80 mg) will be more effective is currently being evaluated in the ongoing clinical trial assessing the safety and tolerability of an oral dose of 20 mg or 80 mg of tafamidis meglumine in patients with TTR-CM (clinicaltrials.gov identifier NCT01994889).
This trial was also limited by the relatively small patient numbers. The clinical identification of patients with TTR-CM and their enrollment into clinical studies is restricted by the heterogeneity of symptoms, many of which are nonspecific disease manifestations commonly seen in older persons; by low awareness of the condition; and the ensuing high frequency of misdiagnosis. 9, 29 As a result of the low number of patients enrolled and the relatively small number who did not achieve TTR stabilization, whether TTR-CM patients who fail to achieve consistent TTR stabilization experience more severe disease progression is not known but will be evaluated in larger trials.
In conclusion, this study provides evidence that tafamidis treatment resulted in TTR stabilization in patients with TTR-CM. Consequently, further study of tafamidis in the TTR-CM amyloidosis population is warranted to determine whether TTR-CM disease progression can be modified by this TTR tetramer stabilization treatment.
